Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

News Industry News

FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa

October 20, 2015

News Industry News

Similar Results With Bivalirudin Compared With Heparin Anticoagulation In TAVR Patients

October 15, 2015

News Industry News

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

July 29, 2015

News Industry News

Eagle Pharmaceuticals’ RTU Bivalirudin NDA Accepted for Filing

July 23, 2015

News Industry News

Hospira Announces U.S. Launch of Generic Bivalirudin for Injection

July 16, 2015

News Industry News

NICE recommends once-daily LIXIANA® (edoxaban) for the treatment and prevention of recurrent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in adults

July 13, 2015

News Industry News

UK launch for Daiichi's bloodthinner Lixiana

July 10, 2015

News Industry News

The Medicines Company Authorizes Generic Launch of ANGIOMAX® (bivalirudin)

July 09, 2015

News Industry News

Portola Pharmaceuticals Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban While Four-Factor Prothrombin C

June 25, 2015

News Industry News

Efficacy and Safety Profile of Pradaxa® (dabigatran etexilate) Repeatedly Confirmed

July 23, 2014

News Industry News

New study to investigate dabigatran etexilate for prevention of recurrent stroke in high-risk patients

May 07, 2014

Advertisement

FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa

Similar Results With Bivalirudin Compared With Heparin Anticoagulation In TAVR Patients

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

Eagle Pharmaceuticals’ RTU Bivalirudin NDA Accepted for Filing

Hospira Announces U.S. Launch of Generic Bivalirudin for Injection

NICE recommends once-daily LIXIANA® (edoxaban) for the treatment and prevention of recurrent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in adults

UK launch for Daiichi's bloodthinner Lixiana

The Medicines Company Authorizes Generic Launch of ANGIOMAX® (bivalirudin)

Portola Pharmaceuticals Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban While Four-Factor Prothrombin C

Efficacy and Safety Profile of Pradaxa® (dabigatran etexilate) Repeatedly Confirmed

New study to investigate dabigatran etexilate for prevention of recurrent stroke in high-risk patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content